Human Insulin Does Not Increase Bladder Cancer Risk

Tseng, Chin‐Hsiao

doi:10.1371/journal.pone.0086517

Cited by 9 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the medications including insulin would affect the risk of lung cancer ( Table 2 ). Our previous studies suggested that insulin use may be associated with some forms of cancer but not all: insulin use is predictive for incidence of [18] but not mortality from [19] non-Hodgkin's lymphoma; it is associated with mortality from but not incidence of bladder cancer [20] , [21] , liver cancer [22] , [23] and pancreatic cancer [24] , [25] ; and it is neither associated with the incidence of nor the mortality from prostate cancer [26] – [28] and gastric cancer [29] , [30] . Putting together the findings of a lack of predictive power of insulin use on the mortality from lung cancer in our recent prospective 12-year follow-up study [31] and the lack of an association with the incidence of lung cancer in the present study ( Table 2 ), the lung may also be one of those less sensitive organs.…”

Section: Discussionmentioning

confidence: 99%

Diabetes but Not Insulin Increases the Risk of Lung Cancer: A Taiwanese Population-Based Study

Tseng

2014

PLoS ONE

Self Cite

View full text Add to dashboard Cite

BackgroundThe trend of lung cancer incidence in Taiwan is unknown, and the association between type 2 diabetes/insulin use and lung cancer is rarely studied.MethodsThe trends of lung cancer incidence in 1979–2007 in the Taiwanese general population were calculated. A random sample of 1,000,000 subjects covered by the National Health Insurance in 2005 was recruited. A total of 494,002 men and 502,948 women and without lung cancer were followed for the annual cumulative incidence of lung cancer in 2005, with calculation of the risk ratios between diabetic and non-diabetic subjects. Logistic regression estimated the adjusted odds ratios for risk factors.ResultsThe trends increased significantly in both sexes (P<0.0001). The sex-specific annual cumulative incidence increased with age in either the diabetic or non-diabetic subjects, but the risk ratios attenuated with age. In logistic regressions, diabetes was associated with a significantly higher risk, with odds ratios (95% confidence interval) for diabetes duration <1, 1–3, 3–5 and ≥5 years versus non-diabetes of 2.189 (1.498-3.200), 1.420 (1.014-1.988), 1.545 (1.132-2.109), and 1.329 (1.063-1.660), respectively. Such an association was not related to a higher detection with chest X-ray examination. Insulin use and medications including oral anti-diabetic drugs, statin, fibrate, and anti-hypertensive agents were not significantly associated with lung cancer. Age, male sex, and chronic obstructive pulmonary disease were positively; but dyslipidemia, stroke and higher socioeconomic status were negatively associated with lung cancer.ConclusionsDiabetes is significantly associated with a higher risk of lung cancer, but insulin use does not increase the risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Diabetes but Not Insulin Increases the Risk of Lung Cancer: A Taiwanese Population-Based Study

Tseng

2014

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent observational study that used data from the CPS II cohort study showed a higher risk of invasive BCa among insulin users compared with diabetics who did not use insulin . A large Taiwanese population‐based study showed a correlation between human insulin use and BCa only in age‐sex adjusted multivariate models, which became insignificant when results were adjusted for all covariates . The same study also showed that human insulin was predictive of BCa mortality after adjusting for all important confounders, thus including DM duration and smoking habit.…”

Section: Evidence Synthesismentioning

confidence: 93%

Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review

et al. 2014

View full text Add to dashboard Cite

Abbreviations & AcronymsAbstract: Metabolic syndrome is a cluster of several metabolic abnormalities, its prevalence is increasing worldwide. To summarize the most recent evidence regarding the relationship between metabolic syndrome, its components and the oncological outcomes in bladder cancer patients, a National Center for Biotechnology Information PubMed search for relevant articles either published or e-published up to March 2014 was carried out by combining the following Patient population, Intervention, Comparison, Outcome terms: metabolic syndrome, obesity, body mass index, hyperglycemia, insulin resistance, diabetes, hypertension, dyslipidemia, bladder cancer, risk, mortality, cancer specific survival, disease recurrence and progression. Metabolic syndrome is a complex, highly prevalent disorder, and central obesity, insulin resistance, dyslipidemia and hypertension are its main components. Published findings would suggest that metabolic syndrome per se might be associated with an increased risk of bladder cancer in male patients, but it did not seem to confer a risk of worse prognosis. Considering the primary components of metabolic syndrome (hypertension, obesity and dyslipidemia), available data are uncertain, and it is no possible to reach a conclusion yet on either a direct or an indirect association with bladder cancer risk and prognosis. Only with regard to type 2 diabetes mellitus, available data would suggest a potential negative correlation. However, as the evaluation of bladder cancer risk and prognosis in patients with metabolic disorders is certainly complex, further studies are urgently required to better assess the actual role of these metabolic disorders.

show abstract

“…A number of co‐morbidities and covariates were determined as a status/diagnosis at the time of entry. These have been described in detail previously and included nephropathy, hypertension, chronic obstructive pulmonary disease (a surrogate for smoking), stroke, ischaemic heart disease, peripheral arterial disease, eye disease, obesity, dyslipidemia, urinary tract disease and other cancers. Other medications included statins, fibrate, angiotensin‐converting enzyme inhibitor and/or angiotensin receptor blocker, calcium channel blocker, aspirin, ticlopidine, clopidogrel, dipyridamole and non‐steroidal anti‐inflammatory drugs.…”

Section: Methodsmentioning

confidence: 99%

Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus

Tseng

2015

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

BACKGROUND:Whether metformin therapy affects ovarian cancer risk in Asian patients with type 2 diabetes mellitus (T2DM) has not been investigated. A time-dependent approach was used to calculate ovarian cancer incidence and estimate hazard ratios by Cox regression for never-users (as referent group), ever-users, and subgroups of metformin exposure (tertiles of cumulative duration and cumulative dose). METHODS: RESULTS: CONCLUSIONS:Metformin use is associated with a decreased risk of ovarian cancer.

show abstract

Human Insulin Does Not Increase Bladder Cancer Risk

Cited by 9 publications

References 21 publications

Diabetes but Not Insulin Increases the Risk of Lung Cancer: A Taiwanese Population-Based Study

Diabetes but Not Insulin Increases the Risk of Lung Cancer: A Taiwanese Population-Based Study

Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review

Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus

Contact Info

Product

Resources

About